A Randomised, Open Label, Parallel Group Phase II Study Comparing the Efficacy and Tolerability of BIBF 1120 Versus Sunitinib in Previously Untreated Patients With Renal Cell Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Aug 2017
At a glance
- Drugs Nintedanib (Primary) ; Sunitinib
- Indications Renal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 03 Aug 2017 Planned End Date changed from 1 Aug 2017 to 15 Aug 2018.
- 03 Aug 2017 Planned primary completion date changed from 1 Aug 2017 to 15 Aug 2018.
- 07 Dec 2016 Planned End Date changed from 1 Feb 2017 to 1 Aug 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History